CSE: SURE | OTCQB: SURNF

The Next Frontier of GLP-1 Science is Micro-Cap
SureNano Science Ltd. is advancing GEP-44, a patented triple-agonist peptide developed at Syracuse University that are designed to address the GI tolerability and injection-burden limitations of first-generation GLP-1 drugs, with a planned pathway through IND-enabling studies toward Phase 1 clinical trials.
View Corporate Presentation
Adults projected to be living with obesity globally by 2030
0 B
Projected GLP-1 therapeutic market by 2030
$ 0 B
Adverse events attributed to GI side effects in current market-leading GLP-1 drugs
> 0 %
Patent protection horizon for GEP-44 peptide technology (US 20220204581A1)
0

Latest News: SureNano Science Ltd. Acquires GlucaPharm Inc.,Advancing Second-Generation FDA Pathway GLP-1 Drug Development

SureNANO EMULSIFIER logo: the word 'SureNANO' in blue and orange with a dotted circular motif to the right.

CSE: SURE | OTCQB: SURNF

  • Outstanding Shares: 42,008,799
  • Fully Diluted: 59,108,799
  • Options: 1,500,000
  • Market Cap: ~$9.8M
  • Website: SureNano.com

Triple-agonist design.
Single-molecule simplicity.

Mechanism of Action

GLP-1 + PYY Y1/Y2 Triple Agonism

GEP-44 is a novel, monomeric peptide developed at Syracuse University that simultaneously activates three receptor pathways — combining the appetite-suppression and glucose-regulation effects of GLP-1 agonism with the energy-expenditure and satiety signaling of PYY receptor activity. The compound is patent-protected through 2042.

Triple-agonist design.
Single-molecule simplicity.

Mechanism of Action

GLP-1 + PYY Y1/Y2 Triple Agonism

GEP-44 is a novel, monomeric peptide developed at Syracuse University that simultaneously activates three receptor pathways — combining the appetite-suppression and glucose-regulation effects of GLP-1 agonism with the energy-expenditure and satiety signaling of PYY receptor activity. The compound is patent-protected through 2042.

Investment Thesis

Four reasons the GLP-1 market opportunity may extend well beyond large-cap incumbents

  • Differentiated Science at the Molecule Level

GEP-44 is a monomeric triple-agonist targeting GLP-1, PYY-Y1, and PYY-Y2 receptors simultaneously — a mechanism distinct from approved semaglutide (single agonist) and tirzepatide (dual agonist). Preclinical data suggest a tolerability and efficacy profile that, if replicated in human trials, could address significant unmet need in the current treatment landscape. All preclinical results are subject to the inherent uncertainty of early-stage drug development.

  • Non-Injectable Delivery Pathway

SureNano’s proprietary nanotechnology platform is being developed to enable oral, nasal, and sublingual delivery of GEP-44 — targeting the adherence barrier that currently limits long-term outcomes for injectable GLP-1 patients. Non-injectable delivery is a research objective and has not yet been demonstrated in human clinical settings.

  • Vertically Integrated Structure

The acquisition of GlucaPharm Inc. creates an integrated platform combining an active peptide asset (GEP-44) with SureNano’s delivery technology, public market infrastructure, and a collaboration with an experienced Australian contract research organization for IND-enabling studies. This combination is intended to support a capital-efficient development pathway.

  • Tight Float with Meaningful Insider Alignment

With approximately 42 million shares outstanding and approximately 26% insider ownership as of the most recent disclosure, SureNano’s capital structure reflects meaningful alignment between management and shareholders. Investors are encouraged to review current public filings on SEDAR+ and OTC Markets for the most up-to-date share structure information.

Corporate Presentation